---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-044204"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T05:08:46.634020+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NICE recommends Vir's sotrovimab for COVID-19 in UK; no meaningful 2023 sales expected

## Summary
- NICE final draft guidance recommends sotrovimab for high-risk adults where Paxlovid is contraindicated or unsuitable.
- Recommendation based on cost-effectiveness evaluation of sotrovimab.
- No meaningful additional UK sales of sotrovimab anticipated in 2023 due to existing inventory.
- Sotrovimab (Xevudy) authorized in over 40 countries; not authorized in the US.

## SEC filing metadata
- accession: 0001193125-23-044204
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312523044204/0001193125-23-044204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312523044204/d444727d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-044204
- JSON: https://secwatch.observer/filing/0001193125-23-044204.json
- Plain text: https://secwatch.observer/filing/0001193125-23-044204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.